Display options
Cite
van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, et al. Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. Clin Cancer Res. 2021;27(22):6106-6114doi: 10.1158/1078-0432.CCR-21-1104.
van der Wijngaart, H., Hoes, L. R., van Berge Henegouwen, J. M., van der Velden, D. L., Zeverijn, L. J., Roepman, P., van Werkhoven, E., de Leng, W. W. J., Jansen, A. M. L., Mehra, N., Robbrecht, D. G. J., Labots, M., de Groot, D. J. A., Hoeben, A., Hamberg, P., Gelderblom, H., Voest, E. E., & Verheul, H. M. W. (2021). Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(22), 6106-6114. https://doi.org/10.1158/1078-0432.CCR-21-1104
van der Wijngaart, Hanneke, et al. "Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,22 (2021): 6106-6114. doi: https://doi.org/10.1158/1078-0432.CCR-21-1104
van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW. Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. Clin Cancer Res. 2021 Nov 15;27(22):6106-6114. doi: 10.1158/1078-0432.CCR-21-1104. Epub 2021 Sep 02. PMID: 34475104.
Copy Download .nbib Format: NLM
Share it on

Clin Cancer Res. 2021 Nov 15;27(22):6106-6114. doi: 10.1158/1078-0432.CCR-21-1104. Epub 2021 Sep 02.

Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.

Clinical cancer research : an official journal of the American Association for Cancer Research

Hanneke van der Wijngaart, Louisa R Hoes, J Maxime van Berge Henegouwen, Daphne L van der Velden, Laurien J Zeverijn, Paul Roepman, Erik van Werkhoven, Wendy W J de Leng, Anne M L Jansen, Niven Mehra, Debbie G J Robbrecht, Mariette Labots, Derk Jan A de Groot, Ann Hoeben, Paul Hamberg, Hans Gelderblom, Emile E Voest, Henk M W Verheul

Affiliations

  1. Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  2. Oncode Institute, Utrecht, the Netherlands.
  3. Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  4. Department of Medical Oncology, Leiden University Medical Center, Rapenburg, Leiden, the Netherlands.
  5. Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  6. Hartwig Medical Foundation, Amsterdam, the Netherlands.
  7. Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  8. Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
  9. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  10. Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  11. Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands.
  12. Department of Medical Oncology, Maastricht University Medical Center, Maastricht, the Netherlands.
  13. Department of Internal Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, the Netherlands.
  14. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands. [email protected].

PMID: 34475104 DOI: 10.1158/1078-0432.CCR-21-1104

Abstract

PURPOSE: To assess the efficacy of olaparib, a PARP inhibitor (PARPi) in patients with tumors with

PATIENTS AND METHODS: Patients with treatment-refractory

RESULTS: Twenty-four evaluable patients with nine different tumor types harboring

CONCLUSIONS: These data indicate that using PARPis is a promising treatment strategy for patients with non-

©2021 American Association for Cancer Research.

References

  1. Liang F, Han M, Romanienko PJ, Jasin M. Homology-directed repair is a major double-strand break repair pathway in mammalian cells. Proc Natl Acad Sci U S A. 1998;95:5172–7. - PubMed
  2. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med. 2009;361:1475–85. - PubMed
  3. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25:5864–74. - PubMed
  4. Foulkes WD, Knoppers BM, Turnbull C. Population genetic testing for cancer susceptibility: founder mutations to genomes. Nat Rev Clin Oncol. 2016;13:41–54. - PubMed
  5. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–6. - PubMed
  6. Nielsen FC, van Overeem Hansen T, Sorensen CS. Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer. 2016;16:599–612. - PubMed
  7. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15. - PubMed
  8. Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–28. - PubMed
  9. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;4:511–8. - PubMed
  10. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001;7:263–72. - PubMed
  11. Riaz N, Blecua P, Lim RS, Shen R, Higginson DS, Weinhold N, et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nat Commun. 2017;8:857. - PubMed
  12. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2007;96:11–5. - PubMed
  13. Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019;571:576–9. - PubMed
  14. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21. - PubMed
  15. Gallmeier E, Kern SE. Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition. Cancer Biol Ther. 2005;4:703–6. - PubMed
  16. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–7. - PubMed
  17. Hartwell L. Theoretical biology. A robust view of biochemical pathways. Nature. 1997;387:8557. - PubMed
  18. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5:689–98. - PubMed
  19. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-Repair defects and olaparib in metastatic prostate cancer. New Engl J Med. 2015;373:1697–708. - PubMed
  20. Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:162–74. - PubMed
  21. Sandhu SK, Hussain M, Mateo J, Fizazi K, Saad F, Shore N, et al. - PubMed
  22. Coleman RL, Oza AM, Lorusso D, Investigators A. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 390, pg 1949, 2017). Lancet. 2017;390:1948. - PubMed
  23. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. New Engl J Med. 2019;381:2391–402. - PubMed
  24. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New Engl J Med. 2018;379:753–63. - PubMed
  25. van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574:127–31. - PubMed
  26. Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–84. - PubMed
  27. Bins S, Cirkel GA, Gadellaa-Van Hooijdonk CG, Weeber F, Numan IJ, Bruggink AH, et al. Implementation of a multicenter biobanking collaboration for next-generation sequencing-based biomarker discovery based on fresh frozen pretreatment tumor tissue biopsies. Oncologist. 2017;22:33–40. - PubMed
  28. Jung SH, Lee T, Kim K, George SL. Admissible two-stage designs for phase II cancer clinical trials. Stat Med. 2004;23:561–9. - PubMed
  29. Simon R. Optimal 2-stage designs for Phase-II clinical-trials. Control Clin Trials. 1989;10:1–10. - PubMed
  30. van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, et al. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. Ann Oncol. 2019;30:663–5. - PubMed
  31. Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019;575:210–6. - PubMed
  32. Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45:D777–D83. - PubMed
  33. Nguyen L, Martens JWM, Van Hoeck A, Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020;11:5584. - PubMed
  34. Van De Haar J, Hoes LR, Roepman P, Cuppen E, Wessels LF, Voest EE. Genomic evolution of metastatic tumours under therapeutic pressure. Ann Oncol. 2020;31:S274–S. - PubMed
  35. Shimelis H, Mesman RLS, Von Nicolai C, Ehlen A, Guidugli L, Martin C, et al. BRCA2 hypomorphic missense variants confer moderate risks of breast cancer. Cancer Res. 2017;77:2789–99. - PubMed
  36. Naipal KAT, Verkaik NS, Ameziane N, van Deurzen CHM, ter Brugge P, Meijers M, et al. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res. 2014;20:4816–26. - PubMed
  37. Fukumoto T, Zhu HR, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, et al. N6-methylation of adenosine of Fzd10 mRNA contributes to parp inhibitor resistance. Cancer Res. 2019;79. - PubMed
  38. Angus L, Smid M, Wilting SM, van Riet J, Van Hoeck A, Nguyen L, et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet. 2019;51:1450–8. - PubMed
  39. André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013;19:3693–702. - PubMed
  40. Brunello E, Brunelli M, Bogina G, Caliò A, Manfrin E, Nottegar A, et al. FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. J Exp Clin Cancer Res. 2012;31:103. - PubMed
  41. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70:2085–94. - PubMed
  42. Wang L, Zhang P, Molkentine DP, Chen C, Molkentine JM, Piao H, et al. TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects. Oncogene. 2017;36:820–8. - PubMed
  43. Molkentine JM, Molkentine DP, Bridges KA, Xie T, Yang L, Sheth A, et al. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. Int J Radiat Biol. 2021;97:1121–8. - PubMed
  44. Liu L, Zhou W, Cheng C-T, Ren X, Somlo G, Fong MY, et al. TGFbeta induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes. Mol Cancer Res. 2014;12:1597–609. - PubMed
  45. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. Plos Med. 2006;3:1865–76. - PubMed
  46. Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017;9:eaal5148. - PubMed
  47. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091–102. - PubMed
  48. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–92. - PubMed
  49. Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New Engl J Med. 2018;379:2495–505. - PubMed
  50. Robson M, Im S-A, Senkus Eż, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New Engl J Med. 2017;377:523–33. - PubMed
  51. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317–27. - PubMed
  52. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28:2512–9. - PubMed
  53. Jiang X, Li X, Li W, Bai H, Zhang Z. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med. 2019;23:2303–13. - PubMed
  54. Roepman P, de Bruijn E, van Lieshout S, Schoenmaker L, Boelens MC, Dubbink HJ, et al. Clinical validation of whole genome sequencing for routine cancer diagnostics. J Mol Diagn 2021. 23:816–33. - PubMed
  55. Monkhorst K, Samsom K, Schipper L, Roepman P, Bosch L, de Bruijn E, et al. Validation of whole genome sequencing in routine clinical practice. Ann Oncol. 2020;31:S784–S. - PubMed

Publication Types